Dr. David I. Bernstein, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
Medicare and federal program status
Opted out of Medicare from May 22, 2025 through May 22, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated July 15, 2025). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
OH license 35043186 -
Clinical & Laboratory Immunology (Internal Medicine) Physician
OH license 35 043186 -
Internal Medicine Physician
OH license 35 043186
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 458
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 236 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 116 | 73 |
| Established patient office or other outpatient visit, 20-29 minutes | 62 | 52 |
| Professional service for multiple injections of allergen | 62 | 16 |
| New patient office or other outpatient visit, 45-59 minutes | 43 | 43 |
| Test to measure expiratory airflow and volume | 21 | 21 |
| Test to measure the level of nitric oxide gas | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in Cincinnati, OH | 113 |
| Prednisone Other prescribers in Cincinnati, OH | 92 |
| Levocetirizine Dihydrochloride Other prescribers in Cincinnati, OH | 69 |
| Fluticasone Propionate Other prescribers in Cincinnati, OH | 64 |
| Montelukast Sodium Other prescribers in Cincinnati, OH | 60 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Cincinnati, OH | 56 |
| Qvar Redihaler (beclomethasone dipropionate) | 47 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Cincinnati, OH | 45 |
| Doxepin Hcl Other prescribers in Cincinnati, OH | 42 |
| Famotidine Other prescribers in Cincinnati, OH | 42 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 40 payments worth $3,209 in total to this clinician.
| Genzyme Corporation | $2,448 |
|---|---|
| Stryker Corporation | $212 |
| Novartis Pharmaceuticals Corporation | $153 |
| Biocryst US Sales Co., LLC | $51.00 |
| Blueprint Medicines Corporation | $48.00 |
| Azurity Pharmaceuticals, Inc. | $41.59 |
| AstraZeneca Pharmaceuticals LP | $34.46 |
| Leo Pharma Inc. | $28.95 |
| Consulting Fee | $2,092 |
|---|---|
| Food and Beverage | $1,117 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Apr 2, 2025 | Consulting Fee | $2,070 |
| Adma Biomanufacturing LLC Feb 4, 2025 | Consulting Fee | $18.35 |
| Adma Biomanufacturing LLC Jan 1, 2025 | Consulting Fee | $4.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $405,095 in research payments for these studies, mostly to the institutions running them.
- Characterization of hsv inhibitors in the HSV2 guinea pig model of infection
Pfizer Inc. - A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Eli Lilly and Company · Active, not recruiting · NCT06339008 - A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - A multi-centre, single arm, open-label extension study to evaluate the
GlaxoSmithKline, LLC. - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
AstraZeneca Pharmaceuticals LP - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.